Evidence map›Paper›PMID 37980767›Full record

Trial reportGynecologic oncology2023

Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, Matthew Burnell, Ranjit Manchanda, Jatinderpal Kalsi, Naveena Singh, Robert Woolas, Aarti Sharma, Karin Williamson and 8 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00058032 (United Kingdom Collaborative Trial Of Ovarian Cancer Screening), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00058032 nacompletednot on this map

United Kingdom Collaborative Trial Of Ovarian Cancer Screening

TypeinterventionalSponsorUniversity College, LondonRan2001 to 2020Enrolled202,638ConditionsOvarian CancerArmsscreening questionnaire administration, annual screening
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 2 countries.

James DilleyDepartment of Gynaecological Oncology, Barts Health NHS Trust, London, UK.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK; Department of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
Andy RyanMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Matthew BurnellMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Ranjit ManchandaDepartment of Gynaecological Oncology, Barts Health NHS Trust, London, UK; Wolfson Institute of Population Health, CRUK Barts Cancer Centre, Queen Mary University of London, London, UK.
Jatinderpal KalsiDepartment of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
Naveena SinghDepartment of Cellular Pathology, Barts Health NHS Trust, London, UK.
Robert WoolasDepartment of Gynaecological Oncology, Queen Alexandra Hospital, Portsmouth, UK.
Aarti SharmaDepartment of Obstetrics and Gynaecology, University Hospital of Wales, Cardiff, UK.
Karin WilliamsonDepartment of Gynaecological Oncology, Nottingham University Hospitals, Nottingham, UK.
Tim MouldDepartment of Gynaecological Oncology, University College London Hospitals NHS Trust, London, UK.
Lesley FallowfieldSussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Sussex, UK.
Stuart CampbellCreate Health London, London, UK.
Steven J SkatesMassachusetts General Hospital and Harvard Medical School, Harvard, MA, USA.
Alistair McGuireLondon School of Economics, London, UK.
Mahesh ParmarMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Ian JacobsDepartment of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK. Electronic address: u.menon@ucl.ac.uk.
University College London · GBBarts Health NHS Trust · GBMRC Clinical Trials Unit at UCL · GBBrighton and Sussex Medical School · GBCREATe Centre · GBLondon School of Economics and Political Science · GBMassachusetts General Hospital · USNottingham University Hospitals NHS Trust · GBQueen Alexandra Hospital · GBQueen Mary University of London · GBUniversity Hospital of Wales · GB

Funding

Cancer Research UK C1479/A2884Medical Research Council G0801228Medical Research Council G9901012Medical Research Council MC_UU_00004/01Medical Research Council MC_UU_12023/28Medical Research Council MR_UU_12023
6 · The paper itself

Abstract

objectiveUKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed (CD) cancers.

methodsIn UKCTOCS, 202638 postmenopausal women, aged 50-74 were randomly allocated (April 17, 2001-September 29, 2005) 2:1:1 to no screening or annual screening till Dec 31,2011, using a multimodal or ultrasound strategy. Follow-up was through national registries. An outcomes committee adjudicated on OC diagnosis, histotype, stage. Eligible women were those diagnosed with iEOC at primary censorship (Dec 31, 2014). Symptom details were extracted from trial clinical-assessment forms and medical records. Descriptive statistics were used to compare symptoms in PC versus CD women with early (I/II) and advanced (III/IV/unable to stage) stage high-grade-serous (HGSC) cancer. ISRCTN-22488978; ClinicalTrials.gov-NCT00058032.

results1133 (286PC; 847CD) women developed iEOC. Median age (years) at diagnosis was earlier in PC compared to CD (66.8PC, 68.7CD, p = 0.0001) group. In the PC group, 48% (112/234; 90%, 660/730CD) reported symptoms when questioned. Half PC (50%, 13/26PC; 36%, 29/80CD; p = 0.213) women with symptomatic HGSC had >1symptom, with abdominal symptoms most common, both in early (62%, 16/26, PC; 53% 42/80, CD; p = 0.421) and advanced (57%, 49/86, PC; 74%, 431/580, CD; p = 0.001) stages. In symptomatic early-stage HGSC, compared to CD, PC women reported more gastrointestinal (change in bowel habits and dyspepsia) (35%, 9/26PC; 9%, 7/80CD; p = 0.001) and systemic (mostly lethargy/tiredness) (27%, 7/26PC; 9%, 7/80CD; p = 0.017) symptoms.

conclusionsOur findings, add to the growing evidence, that we should reconsider what constitutes alert symptoms for early tubo-ovarian cancer. We need a more nuanced complex of key symptoms which is then evaluated and refined in a prospective trial.

Indexed as

Early Detection of CancerOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansProspective StudiesUnited KingdomGOFF indexNICEOvarian cancerSymptomsUKCTOCS

Identifiers

PMID37980767
PMCPMC7616840
OpenAlexW4388800563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.